Erasca stock: RAS pipeline advances toward expanded clinical data

Published on 11/12/2026 at 02:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Erasca stock drew attention as management outlined progress for its RAS cancer pipeline at the Stifel Healthcare Conference. New clinical updates are expected soon.

Erasca advances its RAS pipeline

Management highlighted progress for ERAS-0015 and ERAS-4001 at the Stifel Healthcare Conference.
The company expects expanded ERAS-0015 clinical results at an upcoming scientific meeting in Barcelona.
Future development plans depend on larger studies confirming early efficacy and tolerability signals.

ERAS, US29479A1088, Illustration mit AI erstellt.

Erasca used the Stifel 2026 Healthcare Conference on Wednesday, November 11, to outline progress across its RAS-focused cancer pipeline. In a Investing.com transcript, management pointed to rapid enrollment and encouraging early signals for its lead program, while stressing that larger studies and later-stage trials still have to confirm the findings.

Lead program moves toward larger readout

Erasca said ERAS-0015, a pan-RAS molecular glue inhibitor, is being studied in the AURORAS-1 Phase 1 trial in pancreatic cancer and non-small cell lung cancer. Management cited about five responses among six patients in a U.S. lung cancer cohort at the 16 milligram dose and said expansion cohorts at 24 and 32 milligrams are supporting dose selection.

The company plans an oral plenary presentation at the Triple Meeting in Barcelona. Chief Executive Jonathan Lim said the upcoming presentation should provide a materially expanded update compared with earlier disclosures, as enrollment has progressed faster than expected. The next readout will be important for investors assessing whether early response signals can translate into durable clinical benefit.

Safety remains central to strategy

Management said median relative dose intensity was 100% across the pharmacologically active dose range of 16 to 32 milligrams. Erasca also described its treatment-related adverse-event profile as numerically lower in some categories than those reported for competing RAS therapies, although the company acknowledged that broader comparisons require more mature clinical evidence.

The company is also developing ERAS-4001, a pan-KRAS switch II pocket binder, in the BOREALIS-1 Phase 1 trial. A forthcoming update is expected to cover safety, pharmacokinetics and initial activity. Erasca is studying possible combinations of its programs with panitumumab, pembrolizumab, chemotherapy and Tango Therapeutics' vopimetostat.

Upcoming milestones shape investor focus

Erasca's stated plans include combination results in the first half of 2027 and potential pivotal-trial starts from the first half of 2027. Those timelines remain dependent on dose selection, regulatory discussions and confirmation of efficacy in larger patient groups. The company is also evaluating whether its broad RAS approach could reduce treatment delays linked to mutation-specific testing.

Erasca's oncology positioning

Erasca is a clinical-stage precision oncology company based in San Diego, California. It discovers, develops and seeks to commercialize therapies and combination regimens aimed at the RAS/MAPK signaling pathway across cancers including pancreatic cancer and non-small cell lung cancer. The company is a focused specialist in an area also pursued by oncology developers such as Incyte and Verastem, while its clinical-stage position leaves it earlier in development than more established commercial oncology businesses.